Medicinal chemistry lead for novel metabolic disorders target with successful transitions through HTS evaluation, hit assessment and hit-to-lead generation. Devised and discovered several modulators of a novel nuclear hormone receptor implicated in inflammatory diseases; designed lead used in key proof of concept in vivo experimentsChemistry lead of an external collaboration for several targeted libraries (>1000 compounds).Key contributor to team that delivered several pre-clinical candidates for MDM2/p53 (including AM-8553 and AMG-232). Created multiple enantiopure routes to core intermediates for team. Designed and developed reactions for the synthesis of radiolabeled material. Successful contributor on several hit-to-lead and lead optimization programs: agonists and antagonists for G-PCRs, nuclear hormone receptors, and protein-protein interaction inhibitors in oncology, metabolic disorders, inflammation and neuroscience therapeutic areas.Managed six external full-time equivalents who contributed to the lead optimization effort including synthesizing multiple advanced intermediates and final compounds. Ensured enough material was available to supply internal team.Project manager for collaboration with several international and domestic contract research organizations that delivered intermediates, final compounds, and radiolabeled analogues.Collaborated closely with structural biology and molecular modeling colleagues to design key functionality that resulted in ground breaking compounds. Facilitated 19F NMR fragment screen.Manager for several productive research associates; each received “exceeds” rating (highest performance) while under my supervision.Responsible for the organization and writing of patent procedures and experimental data.

Designed and synthesized key in vivo proof of concept EP2 antagonist for neuroscience. Discovered in vitro tool antagonist of oncology target EDG4/LPA2.Prepared several AMG-853/GPR40 structurally distinct back-up candidates.

Completed the enantioselective total synthesis of the natural product astrogorgin. Developed an innovative route to other members of the eunicellin family.

Developed and implemented a novel method toward the synthesis of C-aryl glycosides including kidamycin.Designed, synthesized, and evaluated conformationally constrained, extended, and reverse turn pseudopeptides as Grb2-SH2 domain inhibitors.

Prepared inhibitors of Src-SH2 domain